Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Per Westermark
Giampaolo Merlini

Showing results (381-390 of 587) with videos related to

Pageof 59
Sort By:
Annals of Neurology|September 24, 2005
A novel AbetaPP mutation exclusively associated with cerebral amyloid angiopathyLaura Obici, Andrea Demarchi, Giulia de Rosa, et al.
Clinical Lymphoma & Myeloma|April 14, 2009
AL amyloidosis associated with IgM monoclonal protein: a distinct clinical entityGiovanni Palladini, Paola Russo, Tiziana Bosoni, et al.
Journal of the American College of Cardiology|November 28, 2015
Diagnosis, Prognosis, and Therapy of Transthyretin AmyloidosisMorie A Gertz, Merrill D Benson, Peter J Dyck, et al.
Blood|February 1, 2015
A practical approach to the diagnosis of systemic amyloidosesCarlos Fernández de Larrea, Laura Verga, Patrizia Morbini, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|May 26, 2020
Pomalidomide and dexamethasone grant rapid haematologic responses in patients with relapsed and refractory AL amyloidosis: a European retrospective series of 153 patientsPaolo Milani, Faye Sharpley, Stefan O Schönland, et al.
Kidney International|January 8, 2015
Tubulointerstitial nephritis is a dominant feature of hereditary apolipoprotein A-I amyloidosisGina Gregorini, Claudia Izzi, Pietro Ravani, et al.
American Journal of Hematology|August 15, 2018
MASS-FIX may allow identification of patients at risk for light chain amyloidosis before the onset of symptomsTaxiarchis Kourelis, David L Murray, Surendra Dasari, et al.
Blood|June 6, 2009
Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation studyDonna E Reece, Vaishali Sanchorawala, Ute Hegenbart, et al.
Neurology|July 26, 2015
Rapid progression of familial amyloidotic polyneuropathy: a multinational natural history studyDavid Adams, Teresa Coelho, Laura Obici, et al.
European Journal of Heart Failure|October 18, 2020
Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension studyThibaud Damy, Pablo Garcia-Pavia, Mazen Hanna, et al.
Pageof 59

Showing results (381-390 of 587) with videos related to

Sort By:
Pageof 59
Annals of Neurology|September 24, 2005
A novel AbetaPP mutation exclusively associated with cerebral amyloid angiopathyLaura Obici, Andrea Demarchi, Giulia de Rosa, et al.
Clinical Lymphoma & Myeloma|April 14, 2009
AL amyloidosis associated with IgM monoclonal protein: a distinct clinical entityGiovanni Palladini, Paola Russo, Tiziana Bosoni, et al.
Journal of the American College of Cardiology|November 28, 2015
Diagnosis, Prognosis, and Therapy of Transthyretin AmyloidosisMorie A Gertz, Merrill D Benson, Peter J Dyck, et al.
Blood|February 1, 2015
A practical approach to the diagnosis of systemic amyloidosesCarlos Fernández de Larrea, Laura Verga, Patrizia Morbini, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|May 26, 2020
Pomalidomide and dexamethasone grant rapid haematologic responses in patients with relapsed and refractory AL amyloidosis: a European retrospective series of 153 patientsPaolo Milani, Faye Sharpley, Stefan O Schönland, et al.
Kidney International|January 8, 2015
Tubulointerstitial nephritis is a dominant feature of hereditary apolipoprotein A-I amyloidosisGina Gregorini, Claudia Izzi, Pietro Ravani, et al.
American Journal of Hematology|August 15, 2018
MASS-FIX may allow identification of patients at risk for light chain amyloidosis before the onset of symptomsTaxiarchis Kourelis, David L Murray, Surendra Dasari, et al.
Blood|June 6, 2009
Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation studyDonna E Reece, Vaishali Sanchorawala, Ute Hegenbart, et al.
Neurology|July 26, 2015
Rapid progression of familial amyloidotic polyneuropathy: a multinational natural history studyDavid Adams, Teresa Coelho, Laura Obici, et al.
European Journal of Heart Failure|October 18, 2020
Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension studyThibaud Damy, Pablo Garcia-Pavia, Mazen Hanna, et al.
Pageof 59